United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.
| Revenue (Most Recent Fiscal Year) | $3.18B |
| Net Income (Most Recent Fiscal Year) | $1.33B |
| PE Ratio (Current Year Earnings Estimate) | 19.48 |
| PE Ratio (Trailing 12 Months) | 18.34 |
| PEG Ratio (Long Term Growth Estimate) | 2.56 |
| Price to Sales Ratio (Trailing 12 Months) | 6.97 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 15.54 |
| Pre-Tax Margin (Trailing 12 Months) | 49.87% |
| Net Margin (Trailing 12 Months) | 41.56% |
| Return on Equity (Trailing 12 Months) | 20.18% |
| Return on Assets (Trailing 12 Months) | 17.98% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.73 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.41 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.39 |
| Book Value per Share (Most Recent Fiscal Quarter) | $149.22 |
| Earnings per Share (Most Recent Fiscal Quarter) | $7.27 |
| Earnings per Share (Most Recent Fiscal Year) | $27.86 |
| Diluted Earnings per Share (Trailing 12 Months) | $27.95 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.89M |
| Free Float | 39.20M |
| Market Capitalization | $21.99B |
| Average Volume (Last 20 Days) | 0.52M |
| Beta (Past 60 Months) | 0.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |